यूरोपीय संघ - फ़िनिश - EMA (European Medicines Agency)

rad neurim pharmaceuticals eec sarl - melatoniini - unihäiriöiden ja ylläpidon häiriöt - psyykenlääkkeiden - melatonin neurim is indicated as monotherapy for the short-term treatment of primary insomnia characterised by poor quality of sleep in patients who are aged 55 or over.

यूरोपीय संघ - फ़िनिश - EMA (European Medicines Agency)

teva gmbh - dimetyylifumaraatti - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunosuppressantit - dimethyl fumarate teva is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).

यूरोपीय संघ - फ़िनिश - EMA (European Medicines Agency)

accord healthcare s.l.u. - dimetyylifumaraatti - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunosuppressantit - dimethyl fumarate accord is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).

यूरोपीय संघ - फ़िनिश - EMA (European Medicines Agency)

sandoz gmbh - natalitsumabin - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunosuppressantit - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 ja 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.